topbanner


Development of microfluidic high-throughput bioassays based on 3D matrix-supported spheroids

The aim of this project is to design novel microfluidic devices with associated procedures that allow the generation and long-term culture of 3D tumour spheroids in order to perform miniaturised high-throughput drug screening assays. Physiologically relevant 3D cancer models are studied using both cell lines and primary human tissue from biopsies for a long period of time within the microfluidics. Microfluidic passive networks are used to maximise the analysis possible from limited cell sources.

wellP1.


Theresa Christ

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

Prof D. Flint, Univ. Strathclyde

Dr M. Boyd, Univ. Strathclyde

Dr J. Edwards, Univ. Glasgow

AMS Biotechnology (Europe) Ltd


LOC platform for high-throughput screening of anti-cancer therapeutics and delivery agents in prostate cancer

The aim of this studentship is to develop a new platform technology to screen emerging anti-cancer therapeutics and delivery agents (i.e., cell-penetrating peptides) being developed in the Beatson Institute and the University of Strathclyde for the treatment of castrate-resistant prostate cancer (CRPC). This studentship will involve developing a microfluidics platform that will enable screening the parameters of drug concentration, cell type, cell penetration in 3D structures and assaying the effects of the drug in a high-throughput format.

wellP2.


Scott Gilmartin

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

Dr G. Burley, Univ. Strathclyde

Prof H. Leung, Beatson Institute


Feasibility study to use enhanced fluorescent imaging and microfluidic technology for high-throughput drug screening of patient derived tumour cell models

The aim of this project is to apply novel microfluidic systems for the 3D culture of primary tumour cell models (http://www.amsbio.com/cancer-model-media-cell-line.aspx). By combining continuous bright-field phase contrast measurements of tumour spheroid response to drugs in microfluidics with fluorescent reporters of pH and metabolic activity, we will provide new sensing techniques to create high-throughput and low cost screening assays using 3D microtumours from patient-derived material, overcoming the current limitations for oncology drug discovery and development of personalised treatment.

wellP3.


Dr Graham Robertson

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

AMS Biotechnology (Europe) Ltd


Feasibility study of using a microfluidic technology for providing immuno-oncology and anticancer drug screening services for personalised medicine

The aim of this project is to develop novel microfluidic prototypes and methodologies to provide advanced drug screening for immune-oncology (I/O) services using physiologically relevant 3D ex-vivo tumour models. Our proprietary technology provides a unique approach to miniaturised compound screening of 3D tumour models from patient derived cancer tissue.

wellP4.


Theresa Mulholland

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

ScreenIn3D Ltd

AMS Biotechnology (Europe) Ltd


Automated microfluidic anticancer drug screening of human tumour biopsies

The aim of this project is to automate an animal-free, anticancer drug testing microfluidic technology that maximises the number of compounds screened on human tumour tissue biopsies. With this project, we address the industrial needs of translating the technology from academic laboratory environments to SME R&D settings.

wellP5.


Karla Paterson

Co-Investigators:

Dr M. Zagnoni, Univ. Strathclyde

AMS Biotechnology (Europe) Ltd

SPONSORS


© Copyright 2017-2019 by Michele Zagnoni